REGULATORY

• PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
  December 5, 2016

• MHLW OKs Add’l Indications for Opdivo, Other Drugs
  December 5, 2016

• Clinical Research Bill Unlikely to Clear Extra Diet
  December 5, 2016

• Panel Shelves Decision on Reimbursement Rate for OTC-Switched Rx
  December 1, 2016

• LDP Group Submits Resolution Calling for “Drug Pricing Agency”
  December 1, 2016

• HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
  December 1, 2016

• Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
  December 1, 2016

• Chuikyo at Odds over Price Maintenance Premium
  December 1, 2016

• Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
  December 1, 2016

• “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
  November 30, 2016

• MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
  November 30, 2016

• Shiozaki Hints at Possible Drug Price Survey in Different Method
  November 30, 2016

• Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
  November 29, 2016

• Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
  November 29, 2016

• LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
  November 28, 2016

• Eltrombopag, Nusinersen Designated as Orphan Drugs
  November 28, 2016

• MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
  November 28, 2016

• Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
  November 28, 2016

• MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
  November 25, 2016

• MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
  November 25, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 259
• 260
• 261
• 262
• 263
• 264
• 265
• 266
• 267
• …
• Next ›
• 最終 »